Participated · Equity · Jun 2026

Founded by economist Leonardo Bursztyn and launched in 2024, Nomo offers a gamified mobile platform that encourages reduced social-media use through collective incentives, competitions, and individual rewards. The app emphasizes social approaches rather than blocking, featuring mechanics like the popular "soquinho" that temporarily locks social apps and awards points; in the first two schools in Rio de Janeiro the feature registered 40,000 soquinhos in a week. Nomo has users in more than 50 countries and has grown largely via institutional partnerships, including a Rio de Janeiro municipal program set to expand to about 500 schools by August and a U.K. program expanding to 52 schools. Early adoption metrics include 88% voluntary participation among students in the first week of the Rio deployments. The startup is testing additional markets in the U.S. and U.K. and is developing a program for older adults in the U.S. in partnership with a wearable health device maker. The company's funding and partnerships include academic- and medical-linked investors, which the founder cites as validation for its mental-health thesis.

Participated · Seed · Mar 2026

Theta Neurotech is developing a non-invasive wearable EEG patch aimed at forecasting seizures. The company pivoted from a broader consumer "Fitbit for the brain" concept toward a medical wedge focused on epilepsy after identifying clinical demand and behavioral considerations for EEG wearables. Theta has raised $2 million in pre-seed funding to support device development, machine-learning research, and an exploratory clinical study. Co-founders Truman Pierson and Christopher Fitz lead the company. The market for seizure monitoring includes invasive and non-invasive competitors, but non-invasive seizure forecasting remains early-stage and challenging. Several rivals are running exploratory studies, and none have yet reached patients.

Participated · Series A · Nov 2025

Onchilles Pharma is pioneering a new class of cancer drugs that exploit the ELANE pathway, a vulnerability tied to elevated histone H1 levels in many tumors. Its lead asset, N17350 (NEU-001), is a tumor-directed biologic shown in preclinical studies to induce rapid, selective tumor cell death and CD8+ T-cell activation across 30 cancer cell lines and 15 in-vivo models, including chemotherapy-resistant and immunologically “cold” tumors. The company has completed GMP manufacturing of more than 5,000 doses and plans to start first-in-human studies in Australia in early 2025, with U.S. enrollment expected mid-2026, aiming for clinical proof-of-concept in the second half of 2026. A second program, NEU-002, a systemic version of the therapy, is on track for development-candidate nomination in early 2026. The firm positions its ELANE-based drugs as next-generation cytotoxics that combine potent tumor killing with immune preservation and activation, potentially addressing a broad range of solid tumors. To date, Onchilles has raised $40 million in Series A financing, including the latest $25 million Series A1 tranche to fund clinical development of N17350.

Participated · Series C · Jul 2025

Ultromics, spun out of the University of Oxford, offers EchoGo®, an artificial-intelligence platform that turns routine cardiac ultrasounds into objective diagnostic reports. The system is trained on one of the world’s largest echocardiography datasets and validated against actual patient outcomes, enabling it to identify subtle markers of HFpEF that are frequently missed in standard workflows. EchoGo has already analyzed more than 430,000 echocardiograms and is deployed in hospitals across the United States and the United Kingdom. Clinical studies cited by the company show the software reached a diagnostic decision in 93% of patients versus 40% for traditional HFpEF risk scores, with consistent accuracy across gender, age and risk groups. Ultromics’ technology is reimbursed by public and private payers and is cleared by the U.S. FDA, underscoring its commercial readiness. Backed by multiple investors and health systems, the company aims to make early identification of heart failure a standard part of cardiac care worldwide.